Group 1 - The stock of Baixin An-B (02185) experienced a significant increase, rising over 15% during trading, reaching a high of 10.77 HKD, marking a new high in over two years, with a closing increase of over 50% the previous day [1] - As of the report, the stock price is up 7.63%, currently at 10.01 HKD, with a trading volume of 61.17 million HKD [1] Group 2 - The American Heart Association (AHA) and the American College of Cardiology (ACC) have released an updated guideline for the prevention, detection, assessment, and management of adult hypertension, which includes significant revisions from the 2017 version [1] - The new guidelines aim to provide more precise clinical practice guidance to reduce cardiovascular disease (CVD) risk, with renal denervation (RDN) being introduced as a newly recommended treatment option [1] - Additionally, there are reports that the Centers for Medicare & Medicaid Services (CMS) in the U.S. has proposed a new RDN insurance coverage plan for patients with uncontrolled hypertension, which is currently in a 30-day public comment period, with a final decision expected by October 8, 2025 [1]
百心安-B早盘一度涨超15% 昨日收涨逾50%RDN进入美国高血压指南